Keywords
How to Cite
Abstract
Erdheim-Chester disease (ECD) is a rare, systemic, non-Langerhans cell histiocytosis. Clinical manifestations vary depending on the organ systems involved. Radiologically, the affectation of long bones by symmetrical metadisphysary sclerosis is characteristic. The infiltration of central nervous system is an independent poor prognosis factor. There are few reports in the medical literature. We discuss two cases because of the infrequency of the disease.
References
2. Mazor RD, Manevich-Mazor M, Shoenfeld Y. Erdheim-Chester Disease: a comprehensive review of the literature. Orphanet J Rare Dis. 2013;8:137.
3. Haroche J1, Arnaud L, Amoura Z. Erdheim-Chester disease. Curr Opin Rheumatol. 2012;24(1):53-9.
4. Arnaud L, Hervier B, Neel A y col. CNS involvement and treatment with interferon-alpha are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53
patients. Blood. 2011;117:2778-2782.
5. Valentini D, Cappelli C, Mizzoni F y col. Erdheim-Chester disease: a non-Langerhans cell histiocytosis. A clinical-case and review of the literature. Clin Ter. 2004;155(5):205-8.
6. Neckman JP, Kim J, Mathur M, Myung P, Girardi M. Diverse cutaneous manifestations of Erdheim-Chester disease in a woman with a history of Langerhans cell histiocytosis. JAAD Case
Rep. 2016;2(2):128-31.
7. Badalian-Very G, Vergilio J, Degar B y col. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116(11):1919-1923.
8. Diamond E, Dagna L, Hyman DM y col. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood. 2014;124(4):483-492.
9. Antony Pan, Terence Doyle, Martin Schlup, Ralf Lubcke, Michael Schultz. Unusual manifestation of Erdheim-Chester disease. BMC Gastroenterol. 2011; 11: 77.
10. Haroche J, Cohen-Aubart F, Emile JF y col. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood. 2013;121(9):1495-1500.
11. Braiteh F1, Boxrud C, Esmaeli B, Kurzrock R. Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-alpha. Blood. 2005 v 1;106(9):2992-4.
12. Azadeh N, Tazelaar HD, Gotway MB, Mookadam F, Fonseca R. Erdheim Chester Disease treated successfully with cladribine. Respir Med Case Rep. 2016;18:37-40.
13. Tzoulis C, Schwarzlmüller T, Gjerde I y col. Excellent response of intramedullary Erdheim-Chester disease to vemurafenib: a case report. BMC Res Notes. 2015;8:171.
14. Veyssier-Belot C, Cacoub P, Caparros-Lefebvre D y col. Erdheim-Chester disease. Clinical and radiologic characteristics of 59 cases. Medicine (Baltimore). 1996 May;75(3):157-69.
15. Arnaud L, Pierre I, Beigelman-Aubry C y col. Pulmonary involvement in Erdheim-Chester disease: a single-center study of thirty-four patients and a review of the literature. Arthritis Rheum. 2010 Nov;62(11):3504-12.
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar